Tagged with DIA

Collaborative Networks Driving Regulatory Transformation in Latin America
EU HTA Regulation: Bringing the European Patient Expertise and Voice into the Decision-Making Processes
What’s Next for Novo Nordisk After CEO Exit & Weight Loss Setbacks?
Bridging the Access Gap to Diabetes Care for Children: New Report
Tackling Diabetes, Obesity & Cardiovascular Disease
Observatory of Good Regulatory Practices: A Pioneering Initiative in Latin America
Melvin D’Souza – Corporate Vice President & General Manager, Novo Nordisk
Generalized Cost-Effectiveness Analysis (GCEA) Framework to Assess the Value of Innovative Therapies
Mark Roithmayr – CEO, Alzheimer’s Drug Discovery Foundation
Nasreen Alfaris – Endocrinology, Diabetes & Obesity Medicine Consultant, King Fahad Medical City
China’s New Drug Approvals Again Hit Record High in 2024
Europe Has a Platform for Driving More Flexible Clinical Trials: It’s Time to Use It
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here